本文選題：替諾福韋酯 + 多重耐藥��； 參考：《中國(guó)藥房》2015年23期

【摘要】：目的:觀察替諾福韋酯(TDF)治療多重耐藥慢性乙型肝炎(CHB)的短期療效及不良反應(yīng)。方法:回顧性分析32例多重耐藥CHB患者病歷資料,所有患者治療前均進(jìn)行乙型肝炎病毒(HBV)耐藥基因檢測(cè),存在多位點(diǎn)耐藥,并給予TDF口服治療。觀察TDF治療前、后丙氨酸氨基轉(zhuǎn)移酶(ALT)復(fù)常率、HBV-DNA陰轉(zhuǎn)率、乳酸、腎功能等指標(biāo)。結(jié)果:治療第3個(gè)月時(shí),ALT復(fù)常率達(dá)100%,治療半年時(shí)HBV-DNA陰轉(zhuǎn)率達(dá)96.88%,治療中患者未出現(xiàn)乳酸水平升高及腎功能異常。結(jié)論:TDF治療多重耐藥CHB療效迅速,未出現(xiàn)明顯不良反應(yīng)。
[Abstract]:Aim: to observe the short-term efficacy and adverse reactions of tenofovir ester (TDF) in the treatment of multi-resistant chronic hepatitis B (CHB). Methods: the medical records of 32 patients with multidrug resistance CHB were retrospectively analyzed. All patients were tested for hepatitis B virus (HBV) resistance gene before treatment and TDF was given orally. Before and after TDF treatment, the recovery rate of alanine aminotransferase (alt) and HBV-DNA negative conversion rate, lactic acid, renal function and so on were observed. Results: the recovery rate of alt was 100 at the 3rd month of treatment, and the negative conversion rate of HBV-DNA was 96.88 at the end of six months. There was no increase in lactic acid level and abnormal renal function in the patients. Conclusion the effect of TDF on multi-drug resistant CHB is rapid and there is no obvious adverse reaction.
【作者單位】： 天津市第二人民醫(yī)院ICU;
【分類號(hào)】：R512.62

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 姚偉明;徐東平;;抗HBV藥物靶位的研究進(jìn)展[J];傳染病信息;2013年06期

2 ;Chinese Consensus on Antiviral Treatment of Chronic Hepatits B Patients with Nucleos(t)ide Analogues[J];Infection International(Electronic Edition);2013年02期

3 黃睿;郝迎迎;張俊;吳超;;拉米夫定聯(lián)合阿德福韋酯與恩替卡韋單藥對(duì)慢性乙型肝炎初治患者療效比較的Meta分析[J];重慶醫(yī)學(xué);2014年01期

4 科技部十二五重大專項(xiàng)聯(lián)合課題組專家;;乙型肝炎病毒相關(guān)肝硬化的臨床診斷、評(píng)估和抗病毒治療的綜合管理[J];實(shí)用肝臟病雜志;2014年02期

5 劉穎;樊蓉;陳簡(jiǎn);鄭志丹;廖寶林;梁攜兒;尹軍花;周秋根;孫劍;;慢性乙型肝炎病毒感染相關(guān)肝硬化患者的腎功能及危險(xiǎn)因素分析[J];南方醫(yī)科大學(xué)學(xué)報(bào);2014年04期

6 何文艷;安紅杰;徐金鳳;;恩替卡韋治療失代償期乙型肝炎肝硬化1例[J];中國(guó)肝臟病雜志(電子版);2014年01期

7 邢卉春;楊松;程丹穎;李s，

本文編號(hào)：2110002